Year: 2018

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that, following a competitive tender process, it has selected Thermo Fisher Scientific, the world leader in serving science, as its drug product (“DP”) and contract development and manufacturing organisation (“CDMO”) for its Kapiglucagon program. Thermo Fisher’s Patheon pharma services…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that six of the six resolutions (Resolutions 1 – 6 inclusive) were duly passed by shareholders. Details are contained in the table below. Resolution For % For Against % Against Withheld 1. To receive…

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that, following a competitive tender process, it has appointed Bachem AG (“Bachem”) as manufacturing partner for the active pharmaceutical ingredient (“API”) for its Kapiglucagon program. Bachem is a leading global peptide and oligonucleotide development and manufacturing partner, supporting pharmaceutical…

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes the recent article published in the scientific journal Autophagy, which reports early-stage research conducted by the University of Murcia (“UoM”) relating to the P140 peptide and its potential application in glioblastoma, an aggressive form of brain cancer. ImmuPharma acknowledges the quality of…

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes today’s announcement by Incanthera plc, “Incanthera”, regarding a corporate update and subsequent Board changes. As part of the Board changes, Tim McCarthy has stepped down as Executive Chairman of Incanthera: Link: https://incanthera.com/ news-media/. To download form Click here

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2025 has also been posted to shareholders today. These documents will be available shortly, in electronic form,…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its Final Results for the twelve months ended 31 December 2025 (the “Period”). Key Highlights (including post Period review) Financials Portfolio P140 technology platform Kapiglucagon Partnering opportunities Management and Board updates Commenting on the statement and outlook…

ImmuPharma plc, (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce the initiation of IND-enabling activities for its Kapiglucagon diabetes program, following the execution of a ‘Work Order’ with specialist pharmaceutical consultancy tranScrip Limited (“tranScrip”). Under the agreement, tranScrip will support the development of the regulatory strategy and the preparation…

TR-1: Standard form for notification of major holdings from Lanstead Capital Investors LP To download form Click here

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, outlines below an open letter to shareholders from the Chairman, Tim McCarthy. This follows on from this week’s announcement, confirming that both resolutions proposed at the General meeting held on Tuesday 7 April 2026, were approved by Shareholders. Dear Shareholders I wanted to take this…